Dr. Scott Halperin
Dalhousie University Node
Canadian Centre for Vaccinology
The node at Dalhousie University includes the Canadian Center for Vaccinology (CCfV) and the Dalhousie Immunology Program.
The CCfV comprises over 60 faculty members in areas of vaccine discovery, vaccine evaluation, and health policy and translation, working on the development of new vaccines and improved vaccine formulations, with an emphasis on delivery systems, adjuvants, and mucosal immunity. The group comprises researchers in bacteriology, molecular biology, virology, and immunology.The CCfV Clinical Trials Research Center (CTRC) evaluates candidate vaccines against infectious diseases (pertussis, hepatitis B, meningococcal disease, herpes simplex, shingles, influenza). CTRC studies have encompassed all phases and age ranges.
A first of its kind in Canada, the Human Vaccine Challenge Unit consists of 10 inpatient beds with state of the art equipment and isolation facilities, to study the efficacy of vaccines and characterize the immune response to infectious challenges. In addition, CCfV’s Health Policy and Translation Group works with members involved in crosscutting thematic interactions with the Discovery and Evaluation groups .
CCfV serves as an entry point into a number of other vaccine-related networks with links to:
- the Immunization Monitoring Program Active (IMPACT),Canada’s surveillance system for vaccine-preventable disease and vaccine- associated adverse events (SOS)
- PHAC/CIHR Influenza Research Network
- PREVENT (Centre of Excellence for Commercialization and Research)
- and the Canadian Association for Immunization Research and Evaluation (CAIRE, a network of over 100 academic and public health investigators)
The Dalhousie University Immunology program consists of members of several research groups including the Dalhousie Inflammation Group (DIG), Atlantic Centre for Transplantation Research, and the Multiple Sclerosis Research Unit. Investigators in these groups have established Dalhousie as an important centre for immunology research, with seventeen principal investigators, two research chairs and five clinician scientists. These investigators have long track records in cell migration research in preclinical and clinical autoimmune diseases, such as arthritis, asthma and MS, and cancer, as well as studies on immunodeficiencies and more recently the mechanisms of action of clinical immunomodulatory agents. Dalhousie heads the Canadian Group on Food Allergy Research funded by the Allergen NCE.